Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

162 Press Releases
DateTitleCompany
24 Jan 12 FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications Millennium: The Takeda Oncology Company,
Published by
Business Wire
20 Jan 12 Takeda Announces Strategic Measures to Achieve Efficiencies for Long-Term Growth Takeda Pharmaceutical Company Limited
22 Dec 11 Takeda snaps up Intellikine to boost cancer pipeline Takeda
21 Dec 11 Takeda to Acquire Intellikine, Adding Two Novel Programs to its Oncology Pipeline Millennium: The Takeda Oncology Company,
Published by
Business Wire
20 Dec 11 Presentations Highlight Results of Clinical Data for MLN8237 and VELCADE® in the Treatment of Lymphoma Millennium: The Takeda Oncology Company,
Published by
Business Wire
13 Dec 11 Presentations Highlight Results of Studies with MLN9708, First Oral Proteasome Inhibitor in Early Stage Clinical Trials in Multiple Myeloma Millennium: The Takeda Oncology Company,
Published by
Business Wire
13 Dec 11 Overall Survival Benefit with VELCADE® Based Therapy in Previously Untreated Multiple Myeloma Patients Maintained After Five Year Follow-Up Millennium: The Takeda Oncology Company,
Published by
Business Wire
22 Nov 11 Takeda Appoints Jostein Davidsen Head of Emerging Markets Takeda
08 Nov 11 More than Thirty Abstracts on VELCADE® and Leading Millennium Pipeline Compounds to be Presented in Oral Sessions at 53rd American Society of Hematology Annual Meeting Millennium: The Takeda Oncology Company,
Published by
Business Wire
02 Nov 11 FDA Approves Addition of Sustained Overall Survival Advantage (5-year follow-up) to Label for VELCADE® in Patients with Previously Untreated Multiple Myeloma Millennium: The Takeda Oncology Company,
Published by
Business Wire
06 Oct 11 Millennium Provides Update on sNDA for VELCADE in Relapsed Follicular Lymphoma Millennium: The Takeda Oncology Company,
Published by
Business Wire
24 Sep 11 Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Pediatric Patients at EMCC Annual Meeting Millennium: The Takeda Oncology Company and Seattle Genetics Inc.,
Published by
Business Wire
16 Sep 11 Millennium Ranked In Top 10 Biotech / Biopharmaceutical Companies For 4th Consecutive Year Millennium: The Takeda Oncology Company,
Published by
Business Wire
19 Jul 11 Millennium Submits Supplemental New Drug Application with FDA for Long-Term Overall Survival Results of VELCADE in Previously Untreated Multiple Myeloma Millennium: The Takeda Oncology Company,
Published by
Business Wire
27 Jun 11 Millennium Announces EMA Acceptance of Marketing Authorization Application for ADCETRIS™ (Brentuximab Vedotin) Millennium: The Takeda Oncology Company,
Published by
Business Wire
23 Jun 11 Data on MLN8237, an Investigational Aurora A Kinase Inhibitor, Presented at International Lymphoma Conference Millennium: The Takeda Oncology Company,
Published by
Business Wire
11 Jun 11 Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Hodgkin Lymphoma at EHA Annual Meeting Millennium: The Takeda Oncology Company,
Published by
Business Wire
10 Jun 11 Data Presentations Showcase Millennium Leadership in Protein Homeostasis at 16th Congress of the European Hematology Association Millennium: The Takeda Oncology Company,
Published by
Business Wire
10 Jun 11 Millennium and Seattle Genetics Present Clinical Data on ADCETRIS™ (Brentuximab Vedotin) in Systemic ALCL at EHA Annual Meeting Millennium: The Takeda Oncology Company,
Published by
Business Wire
07 Jun 11 Novel VELCADE Based Combinations Show High Responses in Heavily Pre-Treated Patients with Relapsed or Refractory Multiple Myeloma Millennium: The Takeda Oncology Company,
Published by
Business Wire
06 Jun 11 Millennium Highlights New Protein Homeostasis Data in Metastatic Melanoma and Other Solid Tumors at American Society of Clinical Oncology Millennium: The Takeda Oncology Company,
Published by
Business Wire
06 May 11 VELCADE Improved Outcomes in Multiple Myeloma Patients After Transplant in Nordic Myeloma Study Millennium: The Takeda Oncology Company,
Published by
Business Wire
05 May 11 Millennium Leadership in Proteasome Inhibition Highlighted in Relapsed/Refractory Multiple Myeloma At IMW Meeting Millennium: The Takeda Oncology Company,
Published by
Business Wire
26 Apr 11 Millennium Submits Two Supplemental NDAs to FDA for VELCADE Millennium: The Takeda Oncology Company,
Published by
Business Wire
15 Apr 11 Anti-Cancer Agent AMG 479 Enters into the Phase III Clinical Trial in Japan Takeda,
Published by
PharmiWeb.com
11 Apr 11 HEPTARES AND TAKEDA INITIATE DRUG DISCOVERY COLLABORATION FOCUSED ON GPCR LINKED TO CNS DISORDERS TAKEDA,
Published by
PharmiWeb.com
11 Apr 11 HEPTARES AND TAKEDA INITIATE DRUG DISCOVERY COLLABORATION FOCUSED ON GPCR LINKED TO CNS DISORDERS Heptares Therapeutics and Takeda Pharmaceutical,
Published by
PharmiWeb.com
04 Feb 11 Journal of Clinical Oncology Publishes Clinical Trial Results of VELCADE Combination in Aggressive Subtypes of Non-Hodgkin Lymphoma Millennium: The Takeda Oncology Company,
Published by
Business Wire
20 Jan 11 Fortune Magazine Names Millennium Among 100 Best Companies to Work For Millennium: The Takeda Oncology Company,
Published by
Business Wire
09 Dec 10 VELCADE Induction Followed by VELCADE Maintenance Improves Clinical Outcomes in Previously Untreated Multiple Myeloma Patients Millennium: The Takeda Oncology Company,
Published by
Business Wire
Advertising